Atherogenic dyslipidemia (AD) alludes to raised degrees of triglycerides (TG) and little thick low-thickness lipoprotein and low degrees of high-thickness lipoprotein cholesterol (HDL-C). Also, raised degrees of enormous TG rich extremely low-thickness lipoproteins, apolipoprotein B and oxidized low-thickness lipoprotein (LDL), and diminished degrees of little high-thickness lipoproteins assumes a basic job in AD. Every one of the three components of AD in essence have been perceived as free hazard factor for cardiovascular illness. Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle.
Editorial: Metabolomics:Open Access
Editorial: Metabolomics:Open Access
Review Article: Metabolomics:Open Access
Review Article: Metabolomics:Open Access
Short Communication: Metabolomics:Open Access
Short Communication: Metabolomics:Open Access
Research Article: Metabolomics:Open Access
Research Article: Metabolomics:Open Access
Review Article: Metabolomics:Open Access
Review Article: Metabolomics:Open Access
Scientific Tracks Abstracts: Molecular and Genetic Medicine
Scientific Tracks Abstracts: Molecular and Genetic Medicine
Scientific Tracks Abstracts: Journal of Tissue Science and Engineering
Scientific Tracks Abstracts: Journal of Tissue Science and Engineering
Posters & Accepted Abstracts: Metabolomics:Open Access
Posters & Accepted Abstracts: Metabolomics:Open Access
Keynote: Metabolomics:Open Access
Keynote: Metabolomics:Open Access
Scientific Tracks Abstracts: Metabolomics:Open Access
Scientific Tracks Abstracts: Metabolomics:Open Access
Metabolomics:Open Access received 895 citations as per Google Scholar report